← Human Trials & Peer-Reviewed Studies
Zolmitriptan-induced growth hormone release in humans: mediation by 5-HT1D receptors?
Plain-language guide to PMID 10463324 (1999): double-blind controlled clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Key Facts
- PMID
- 10463324
- Journal
- Psychopharmacology
- Year
- 1999
- Study type
- Controlled Clinical Trial
- Authors
- Whale R et al. (3 authors)
- DOI
- 10.1007/s002130051052
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a controlled clinical trial.
To investigate the neuroendocrine profile of the 5-HT1B/1D receptor agonist, zolmitriptan, in healthy volunteers.
A further six healthy men were recruited to an equivalent study to examine the effect of ketanserin (a 5-HT receptor antagonist with some preference for 5-HT1D over 5-HT1B receptors) on the growth hormone response to zolmitriptan.
Who Took Part
PubMed indexes the participants as teenagers, adults and middle-aged adults, both men and women.
How the Study Was Run
The researchers set it up as a double-blind, placebo-controlled and crossover study.
As a double-blind Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study, the assignments were hidden from both participants and investigators until the end.
Some participants received a placebo instead of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), giving a reference point.
In the crossover set-up each of the participants took both Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and the comparison in turn, acting as their own control.
Blood samples were taken at 15-min intervals for assay of prolactin and growth hormone.
What Was Measured
Topics PubMed links to this paper include Human Growth Hormone, Oxazoles, Oxazolidinones, Receptor, Serotonin, 5-HT1D, Receptors, Serotonin, Serotonin Receptor Agonists and Sumatriptan.
What This Means in Plain Language
The paper is a double-blind, placebo-controlled and crossover study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Its findings take up roughly 3 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 1999 (Psychopharmacology), a journal based in Germany.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.